A two-vaccine regimen to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical tria. - From ScienceDaily
The investigational vaccines included Ad26.ZEBOV, developed by Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and MVA-BN-Filo, developed by Bavarian Nordic.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), supported the development and testing of the experimental vaccines, beginning with early non-clinical and manufacturing process development.
Both of the vaccines in the regimen use harmless viral vectors, or carriers, to deliver proteins of the Ebola virus, which prompt an immune response.
MVA-BN-Filo uses a modified vaccinia virus Ankara vector to express proteins from various species of Ebola virus, as well as the related Marburg virus.
Previously reported initial results showed the two-vaccine regimen is safe, well-tolerated and induced immune responses in participants eight months after immunization.